Create an Account

Targeting SGLT2 in Clinical Cardiology: Exploring the Benefits in CV risk, Diabetes & Heart Failure

Meeting report with video, highlights and slides of a PACE-CME symposium held during ESC 2018 in Munich on the potential role of SGLT2 inhibition in clinical cardiology

Episodes 1-2 of 2

  • Changing focus in diabetes From glucose to CV risk managementChanging focus in diabetes From glucose to CV risk management
    Targeting SGLT2 in Clinical Cardiology: Exploring the Benefits in CV risk, Diabetes & Heart Failure
    Changing focus in diabetes: From glucose to CV risk management
    • Stephan Jacob, MD
      Stephan Jacob, MD

      Stephan Jacob, MD

  • SGLT inhibition in cardiology What is the profile of benefitSGLT inhibition in cardiology What is the profile of benefit
    Targeting SGLT2 in Clinical Cardiology: Exploring the Benefits in CV risk, Diabetes & Heart Failure
    SGLT2 inhibition in cardiology: What is the profile of benefit?
    • Nikolaus Marx, MD
      Nikolaus Marx, MD

      Nikolaus Marx, MD

LIVE ON REACHMD RADIOBack to live radio
ReachMD Radio

Loading...

00:00
00:00
    Register

    We’re glad to see you’re enjoying PACE-CME…
    but how about a more personalized experience?

    Register for free
    You are now leaving PACE-CME and going to a site run by another organization.

    Press cancel to remain on PACE-CME. Press the link below or the continue button to keep going.